AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7648979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acid medication with or without shock‐wave lithotripsy
Number of subjects: 60
Study 7648979 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstone recurrence
Number of subjects: 60
Study 2256740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 0
Study 2256740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7404184 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload Cu 250
Number of subjects: 604
Study 7404184 — intervention group
Group type: COMPARATOR
Intervention: Lippes loop
Number of subjects: 604
Study 31441031 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Ulcer Prophylaxis (SUP)
Number of subjects: 3291
Study 31441031 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SAPS II score
Number of subjects: 3291
Study 31441031 — intervention group
Group type: EXPERIMENTAL
Intervention: University hospital admission
Number of subjects: 3291
Study 31441031 — intervention group
Group type: EXPERIMENTAL
Intervention: Later CIB episodes
Number of subjects: 3291
Study 28236619 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture adjunctive to zolpidem (AAZ)
Number of subjects: 49
Study 28236619 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback adjunctive to zolpidem (BAZ)
Number of subjects: 49
Study 28236619 — intervention group
Group type: COMPARATOR
Intervention: Control (OZ)
Number of subjects: 49
Study 25667250 — intervention group
Group type: EXPERIMENTAL
Intervention: MI + PI
Number of subjects: 357
Study 25667250 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 357
Study 25667250 — intervention group
Group type: COMPARATOR
Intervention: MI only
Number of subjects: 357
Study 24315664 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2 inhalation during hyperventilation
Number of subjects: 12
Study 24315664 — intervention group
Group type: COMPARATOR
Intervention: Room air during hyperventilation
Number of subjects: 12
Study 24315664 — intervention group
Group type: COMPARATOR
Intervention: 100% O2 during hyperventilation
Number of subjects: 12
Study 21604824 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 0
Study 19444092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg twice daily for 6 weeks
Number of subjects: 27
Study 19444092 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 27
Study 17584199 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial strain imaging by tissue Doppler echocardiography
Number of subjects: 25
Study 17584199 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy controls)
Number of subjects: 25
Study 15064019 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5Gy once daily
Number of subjects: 24
Study 15064019 — intervention group
Group type: COMPARATOR
Intervention: 1.5Gy OD x 12 days
Number of subjects: 24
Study 15064019 — intervention group
Group type: COMPARATOR
Intervention: 0.5Gy TDS x 12 days
Number of subjects: 24
Study 11925292 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate 200 mg
Number of subjects: 105
Study 11925292 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate 100 mg
Number of subjects: 105
Study 11925292 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate 50 mg
Number of subjects: 105
Study 11925292 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate 25 mg
Number of subjects: 105
Study 9819043 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven)
Number of subjects: 0
Study 9819043 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI)
Number of subjects: 0
Study 9819043 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7585167 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2696381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 40
Study 2696381 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 40
Study 326349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole 1.5 g single dose
Number of subjects: 88
Study 326349 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole 2 g single dose
Number of subjects: 88
Study 29958053 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/d)
Number of subjects: 120
Study 29958053 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipidated curcumin
Number of subjects: 120
Study 29958053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29030456 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent decline in serum total homocysteine (tHcy)
Number of subjects: 16867
Study 29030456 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% decline in tHcy
Number of subjects: 16867
Study 29030456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiles of percent decline in tHcy
Number of subjects: 16867
Study 29030456 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent decline in tHcy
Number of subjects: 16867
Study 25457567 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision
Number of subjects: 46
Study 25457567 — intervention group
Group type: COMPARATOR
Intervention: 2D vision
Number of subjects: 46
Study 23295103 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral template intervention
Number of subjects: 14
Study 21592308 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg (evening dose) on day 3, followed by 75 mg b.i.d. on day 4
Number of subjects: 31
Study 21592308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18495694 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) replacement
Number of subjects: 14
Study 17000801 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil high concentration (8 ng mL(‐1))
Number of subjects: 45
Study 17000801 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil low concentration (3 ng mL(‐1))
Number of subjects: 45
Study 17000801 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (control group)
Number of subjects: 45
Study 14561241 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS3 gene polymorphisms (G894T, T‐786C)
Number of subjects: 103
Study 14561241 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS3 gene polymorphisms (T‐786C)
Number of subjects: 103
Study 14561241 — intervention group
Group type: EXPERIMENTAL
Intervention: C242T CYBA polymorphism
Number of subjects: 103
Study 14561241 — intervention group
Group type: EXPERIMENTAL
Intervention: CA repeats
Number of subjects: 103
Study 14561241 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis for NOS3 polymorphisms
Number of subjects: 103
Study 10969252 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-HBV-IPV/Hib (mixed administration)
Number of subjects: 359
Study 10969252 — intervention group
Group type: COMPARATOR
Intervention: DTaP-HBV-IPV + Hib (separate administration)
Number of subjects: 359
Study 10969252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mixed and separate administration
Number of subjects: 359
Study 9122287 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 19
Study 9122287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1386029 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg depot monthly subcutaneously)
Number of subjects: 307
Study 1386029 — intervention group
Group type: COMPARATOR
Intervention: Danazol (200 mg three times a day for 24 weeks)
Number of subjects: 307
Study 1386029 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 307
Study 1386029 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 307
Study 6511088 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (500 mg tablets)
Number of subjects: 24
Study 6511088 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (500 mg enteric-coated pellets)
Number of subjects: 24
Study 30718805 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal multiple micronutrient (MMN) supplementation
Number of subjects: 811
Study 30718805 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant zinc and MMN supplementation
Number of subjects: 811
Study 29155123 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro low mixture (LM)
Number of subjects: 2091
Study 29155123 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IG)
Number of subjects: 2091
Study 26160006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for probability-based selection for active surveillance (AS)
Number of subjects: 619
Study 26160006 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIAS rule-based criteria
Number of subjects: 619
Study 26160006 — intervention group
Group type: COMPARATOR
Intervention: Klotz rule-based criteria
Number of subjects: 619
Study 26160006 — intervention group
Group type: COMPARATOR
Intervention: Johns Hopkins rule-based criteria
Number of subjects: 619
Study 26019334 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg) administered intravenously
Number of subjects: 32
Study 23216417 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol + diet beverage (1.97 ml/kg vodka mixed with 3.94 ml/kg diet Squirt)
Number of subjects: 16
Study 23216417 — intervention group
Group type: COMPARATOR
Intervention: Alcohol + regular beverage (1.97 ml/kg vodka mixed with 3.94 ml/kg Squirt)
Number of subjects: 16
Study 23216417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued go/no-go reaction time task performance
Number of subjects: 16
Study 23216417 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective measures
Number of subjects: 16
Study 22030228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 49
Study 22030228 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 49
Study 22030228 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 49
Study 22030228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese and Butter
Number of subjects: 49
Study 18487136 — intervention group
Group type: COMPARATOR
Intervention: CD-ROM feedback
Number of subjects: 292
Study 18487136 — intervention group
Group type: EXPERIMENTAL
Intervention: Print feedback
Number of subjects: 292
Study 16950463 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mode
Number of subjects: 25
Study 16950463 — intervention group
Group type: EXPERIMENTAL
Intervention: AM-mode
Number of subjects: 25
Study 16950463 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DSI
Number of subjects: 25
Study 16950463 — intervention group
Group type: COMPARATOR
Intervention: TDD
Number of subjects: 25
Study 12690273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleconaril, 5 mg/kg/dose orally three times a day for 7 days
Number of subjects: 21
Study 12690273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10714858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk with whey protein concentrate
Number of subjects: 20
Study 10714858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8960577 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 2418
Study 8960577 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirin treatment
Number of subjects: 2418
Study 7932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Color Doppler Flow Imaging (QCDFI)
Number of subjects: 224
Study 7932956 — intervention group
Group type: COMPARATOR
Intervention: Conventional duplex scanning
Number of subjects: 224
Study 3070414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzer re-use (6 uses of each dialyzer)
Number of subjects: 0
Study 30319652 — intervention group
Group type: EXPERIMENTAL
Intervention: QBECO treatment
Number of subjects: 0
Study 27567279 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 362
Study 27567279 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil plus cisplatin
Number of subjects: 362
Study 25706882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanezumab, a humanised IgG monoclonal antibody against Nogo‐A protein, administered intravenously in a first‐in‐human study.
Number of subjects: 76
Study 25706882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanezumab, administered intravenously, with one or two doses.
Number of subjects: 76
Study 23154299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored CR program
Number of subjects: 236
Study 23154299 — intervention group
Group type: COMPARATOR
Intervention: Traditional CR program
Number of subjects: 236
Study 23154299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CR programs
Number of subjects: 236
Study 22738802 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg/day
Number of subjects: 430
Study 22738802 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg/day
Number of subjects: 430
Study 22738802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 21560631 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily + UDCA 10 mg/kg daily
Number of subjects: 62
Study 21560631 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily
Number of subjects: 62
Study 18606589 — intervention group
Group type: EXPERIMENTAL
Intervention: econazole with polycarbophil (group A)
Number of subjects: 180
Study 18606589 — intervention group
Group type: COMPARATOR
Intervention: econazole without polycarbophil (group B)
Number of subjects: 180
Study 15976927 — intervention group
Group type: COMPARATOR
Intervention: Classroom-level intervention promoting social acceptance through cooperative games and teamwork-based activities.
Number of subjects: 24
Study 11939441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal tube placement with flexible lightwand in trachea (n=40)
Number of subjects: 1000
Study 11939441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal tube placement with flexible lightwand in oesophagus (n=40)
Number of subjects: 1000
Study 11939441 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible lightwand-guided intubation via ILM in study 2 (n=1,000)
Number of subjects: 1000
Study 11939441 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol for correcting oesophageal intubation
Number of subjects: 1000
Study 11939441 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection method using light glow and capnography
Number of subjects: 1000
Study 10516448 — intervention group
Group type: EXPERIMENTAL
Intervention: MIB1 score
Number of subjects: 207
Study 10516448 — intervention group
Group type: EXPERIMENTAL
Intervention: M/V index
Number of subjects: 207
Study 10516448 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary status
Number of subjects: 207
Study 10516448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor grade
Number of subjects: 207
Study 10516448 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFr
Number of subjects: 207
Study 10516448 — intervention group
Group type: EXPERIMENTAL
Intervention: p53
Number of subjects: 207
Study 8818434 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 428
Study 8818434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 1408685 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast media (iopamidol)
Number of subjects: 20
Study 1408685 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast media (ioxaglate)
Number of subjects: 20
Study 3932054 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms q.i.d.
Number of subjects: 10
Study 3932054 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 25 micrograms q.i.d.
Number of subjects: 10
Study 3932054 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 25 micrograms q.i.d. with aspirin 650 mg q.i.d.
Number of subjects: 10
Study 3932054 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 10
Study 31029534 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μL drop of Refresh® (visit C)
Number of subjects: 18
Study 31029534 — intervention group
Group type: COMPARATOR
Intervention: No drops (visits A and B)
Number of subjects: 18
Study 31029534 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective and objective TF grading techniques
Number of subjects: 18
Study 31029534 — intervention group
Group type: COMPARATOR
Intervention: Ocular lubricants
Number of subjects: 18
Study 28611132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hole Implantable Collamer Lens (ICL), STAAR Surgical
Number of subjects: 351
Study 26590023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy plus pharmacotherapy
Number of subjects: 199
Study 26590023 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care (three-session psycho-educational intervention) plus pharmacotherapy
Number of subjects: 199
Study 26590023 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care plus pharmacotherapy
Number of subjects: 199
Study 24226057 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART (within 2 weeks after TB treatment initiation)
Number of subjects: 806
Study 24226057 — intervention group
Group type: COMPARATOR
Intervention: Later ART (8-12 weeks after TB treatment)
Number of subjects: 806
Study 24226057 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART with CD4 <50 cells/mm³
Number of subjects: 806
Study 24226057 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART with CD4 ≥50 cells/mm³
Number of subjects: 806
Study 24226057 — intervention group
Group type: COMPARATOR
Intervention: Later ART with CD4 <50 cells/mm³
Number of subjects: 806
Study 24226057 — intervention group
Group type: COMPARATOR
Intervention: Later ART with CD4 ≥50 cells/mm³
Number of subjects: 806
Study 24226057 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART
Number of subjects: 806
Study 24226057 — intervention group
Group type: COMPARATOR
Intervention: Later ART
Number of subjects: 806
Study 24226057 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TB IRIS cases
Number of subjects: 806
Study 24226057 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TB IRIS severity
Number of subjects: 806
Study 24226057 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS management
Number of subjects: 806
Study 22576712 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (Lactobacillus, Bifidobacterium, and galactooligosaccharides) for 8 weeks
Number of subjects: 47
Study 22576712 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy
Number of subjects: 47
Study 22576712 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 20209644 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 42
Study 20209644 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine
Number of subjects: 42
Study 20209644 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab only
Number of subjects: 42
Study 20209644 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine and Abciximab
Number of subjects: 42
Study 20209644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17507582 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives for fast retrieval-based performance
Number of subjects: 0
Study 17507582 — intervention group
Group type: COMPARATOR
Intervention: Task instructions focused on speed and accuracy
Number of subjects: 0
Study 16238791 — intervention group
Group type: COMPARATOR
Intervention: Dietary egg exclusion
Number of subjects: 0
Study 16238791 — intervention group
Group type: COMPARATOR
Intervention: Unmodified healthy diet
Number of subjects: 0
Study 11753128 — intervention group
Group type: COMPARATOR
Intervention: Plant extracts
Number of subjects: 0
Study 10429851 — intervention group
Group type: EXPERIMENTAL
Intervention: Compat Sandoz
Number of subjects: 150
Study 10429851 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocare Nutricia
Number of subjects: 150
Study 10429851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sherwood
Number of subjects: 150
Study 10429851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-term evaluation
Number of subjects: 150
Study 7590485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal interferon-alpha 2b (5-30 x 10(6) units) administered on Day 1 (+/- Day 8)
Number of subjects: 15
Study 7590485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cis-platinum (75 mg/m2) plus cyclophosphamide (750 mg/m2) administered on Day 2
Number of subjects: 15
Study 7590485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal therapy
Number of subjects: 15
Study 7590485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chemotherapy
Number of subjects: 15
Study 1545080 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 117
Study 1545080 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine plus isosorbide dinitrate
Number of subjects: 117
Study 1545080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 117
Study 3918969 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 cGy/fraction X 4 days/week (Group B)
Number of subjects: 58
Study 3918969 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose/fraction (180‐200 cGy) X 5 days/week (Group A)
Number of subjects: 58
Study 31083074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-free, adhesive bone conduction device
Number of subjects: 13
Study 31083074 — intervention group
Group type: COMPARATOR
Intervention: Conventional bone conduction device
Number of subjects: 13
Study 31083074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 13
Study 30254071 — intervention group
Group type: EXPERIMENTAL
Intervention: methylation-derived neutrophil-to-lymphocyte ratio (mdNLR)
Number of subjects: 319
Study 26936138 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (October-December to April-June)
Number of subjects: 426
Study 26936138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanning
Number of subjects: 426
Study 26936138 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 426